alexa Resistance to Co-Amoxiclav (Augmentin) in Community-Acquired and Nosocomial Pleural Infections

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Resistance to Co-Amoxiclav (Augmentin) in Community-Acquired and Nosocomial Pleural Infections

Objective: To describe the ecology in pleural infections, where nosocomial and community-acquired infections may have different ecology. Methods: retrospective single center study. Any subject admitted in intensive care unit with a diagnosis of complicated pleural effusion (presence of macroscopic pus, or sero-fibrinous pleural effusion with pH <7.2 or LDH >1000 or pleural glucose <0, 4 g/L, and signs of infection or positive bacteriological sampling) were included. Results: From 2006 to 2012, 57 patients were included. Four strains of “Multi-resistant” bacteria were reported in 3 patients with community-acquired pleural infection. As a whole 3 out of 57 (5%) patients had microorganisms (not including candida and mycobacteria) resistant to co-amoxiclav. It was not different between nosocomial and community-acquired pleural infections. Conclusion: Our study found resistance to co-amoxiclav in 14% and “multi-drug resistance” in 8% of the patients with community-acquired pleural infection.

Citation: Champion S, Annonay M (2015) Resistance to Co-Amoxiclav (Augmentin) in Community-Acquired and Nosocomial Pleural Infections. J Pulm Respir Med 5:284. doi:10.4172/2161-105X.1000284

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords